孟鲁司特治疗儿童过敏性紫癜的临床疗效及对Toll样受体和IL-6,IL-8表达的影响

Clinical Efficacy and Affect to IL-6,IL-8 Expression of Montelukast in Treatment of Children Allergic Purpura

目的:研究孟鲁司特治疗儿童过敏性紫癜的临床疗效及对Toll样受体(TLRs)和白介素-6(IL-6)、白介素-8(IL-8)表达的影响。方法:选取2011年2月到2015年2月我院收治的儿童过敏性紫癜患者150例,按照随机数字表法将患者分为研究组和对照组,每组75例,对照组给予常规治疗,研究组在对照组的基础上给予孟鲁司特,应用荧光定量PCR技术测量TLR2、TLR5和TLR9mRNA基因表达情况,应用酶联免疫吸附(EILSA)法测定患者血清中IL-6和IL-8水平,并比较两组临床疗效,皮疹消退、关节肿痛以及腹痛缓解时间。结果:研究组总有效率97.3%(73/75)显著高于对照组81.3%(61/75),两组比较差异具有统计学意义(P<0.05);研究组皮疹消退、关节肿痛以及腹痛缓解时间均显著短于对照组,两组比较差异具有统计学意义(P<0.05);两组治疗后TLR2、TLR5和TLR9m RNA表达水平显著低于治疗前,且研究组显著低于对照组,比较差异具有统计学意义(P<0.05);两组治疗后IL-6和IL-8水平显著低于治疗前,且研究组显著低于对照组,比较差异具有统计学意义(P<0.05)。结论:孟鲁司特治疗儿童过敏性紫癜具有较好的临床疗效,能显著降低TLRs、IL-6和IL-8水平。

Objective： To study the clinical efficacy and affect to Toll-like receptor （TLRs）and interleukin-6 （IL-6）, interleukin-8 （IL-8）expression of montelukast in treatment of children allergic purpura. Methods： 150 cases with children allergic purpura were selected from February 2011 to February 2015, they were divided into study group and the control group according to a random number table, 75 cases in each group, the control group received conventional treatment, the study group was given montelukast on the basis of the control group, TLR2, TLR5 and TLR9 mRNA gene expression were dected in quantitative PCR, IL-6 and IL-8 levels in serum were detected in enzyme-linked immunosorbent assay （ELISA）method, and clinical efficacy, rash subsided, joint swelling and pain relief time of two groups were compared. Results： Total efficiency of the study group was 97.3%（73/75）significantly higher than 81.3%（61/75）in the con- trol group, the difference was statistically significant （P〈0.05）; Rash subsided, joint swelling and pain relief time of the study group were significantly shorter than the control group, the difference was statistically significant （P〈0.05）; TLR2, TLR5 and TLR9 mRNA expres- sion levels after treatment of two groups significantly lower than before treatment, and the study group was significantly lower than the control group, the difference was statistically significant （P〈0.05）; IL-6 and IL-8 levels after treatment of two groups significantly lower than before treatment, and the study group was significantly lower than the control group, the difference was statistically significant （P〈0. 05）. Conclusion： Montelukast in treatment of children with allergic purpura have better clinical efficacy, can significantly reduce the TLRs, IL-6 and IL-8 levels.